{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:47:23Z","timestamp":1777614443106,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10067-020-05488-4","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T23:03:02Z","timestamp":1604703782000},"page":"2155-2165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials"],"prefix":"10.1007","volume":"40","author":[{"given":"Zheng-rui","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-long","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,6]]},"reference":[{"issue":"10182","key":"5488_CR1","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter DJ, Bierma-Zeinstra S (2019) Osteoarthritis. Lancet 393(10182):1745\u20131759. https:\/\/doi.org\/10.1016\/S0140-6736(19)30417-9","journal-title":"Lancet"},{"issue":"2","key":"5488_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","volume":"16","author":"W Zhang","year":"2008","unstructured":"Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16(2):137\u2013162. https:\/\/doi.org\/10.1016\/j.joca.2007.12.013","journal-title":"Osteoarthr Cartil"},{"issue":"2","key":"5488_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2","volume":"43","author":"F Wolfe","year":"2000","unstructured":"Wolfe F, Zhao S, Lane N (2000) Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43(2):378\u2013385. https:\/\/doi.org\/10.1002\/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2","journal-title":"Arthritis Rheum"},{"issue":"8 Suppl","key":"5488_CR4","first-page":"S236","volume":"15","author":"RD Altman","year":"2009","unstructured":"Altman RD (2009) Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care 15(8 Suppl):S236\u2013S243","journal-title":"Am J Manag Care"},{"issue":"9","key":"5488_CR5","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1136\/annrheumdis-2012-203164","volume":"73","author":"AR Balanescu","year":"2014","unstructured":"Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR (2014) Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 73(9):1665\u20131672. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203164","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5488_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","volume":"115","author":"PW Mantyh","year":"2011","unstructured":"Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL (2011) Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 115(1):189\u2013204. https:\/\/doi.org\/10.1097\/ALN.0b013e31821b1ac5","journal-title":"Anesthesiology"},{"issue":"7","key":"5488_CR7","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/art.34385","volume":"64","author":"JR Ghilardi","year":"2012","unstructured":"Ghilardi JR, Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, Castaneda-Corral G, Bloom AP, Kuskowski MA, Mantyh PW (2012) Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum 64(7):2223\u20132232. https:\/\/doi.org\/10.1002\/art.34385","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5488_CR8","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/rheumatology\/keq188","volume":"49","author":"DA Walsh","year":"2010","unstructured":"Walsh DA, McWilliams DF, Turley MJ, Dixon MR, Frans\u00e8s RE, Mapp PI, Wilson D (2010) Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 49(10):1852\u20131861. https:\/\/doi.org\/10.1093\/rheumatology\/keq188","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"5488_CR9","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.pain.2011.05.003","volume":"152","author":"N Katz","year":"2011","unstructured":"Katz N, Borenstein DG, Birbara C, Bramson C, Nemeth MA, Smith MD, Brown MT (2011) Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 152(10):2248\u20132258. https:\/\/doi.org\/10.1016\/j.pain.2011.05.003","journal-title":"Pain"},{"issue":"8","key":"5488_CR10","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1110\/ps.035402.108","volume":"17","author":"YN Abdiche","year":"2008","unstructured":"Abdiche YN, Malashock DS, Pons J (2008) Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 17(8):1326\u20131335. https:\/\/doi.org\/10.1110\/ps.035402.108","journal-title":"Protein Sci"},{"key":"5488_CR11","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj 339:b2700. https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"Bmj"},{"issue":"12","key":"5488_CR12","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833\u20131840","journal-title":"J Rheumatol"},{"key":"5488_CR13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.56645\/jmde.v6i14.284","volume":"6","author":"M Tarsilla","year":"2008","unstructured":"Tarsilla M (2008) Cochrane handbook for systematic reviews of interventions. J Multidiscip Eval 6:142\u2013148","journal-title":"J Multidiscip Eval"},{"issue":"7650","key":"5488_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ, Group GW (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"16","key":"5488_CR15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","volume":"363","author":"NE Lane","year":"2010","unstructured":"Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown MT (2010) Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 363(16):1521\u20131531. https:\/\/doi.org\/10.1056\/NEJMoa0901510","journal-title":"N Engl J Med"},{"issue":"12","key":"5488_CR16","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.joca.2011.09.006","volume":"19","author":"H Nagashima","year":"2011","unstructured":"Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C (2011) Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthr Cartil 19(12):1405\u20131412. https:\/\/doi.org\/10.1016\/j.joca.2011.09.006","journal-title":"Osteoarthr Cartil"},{"issue":"6","key":"5488_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.joca.2011.01.009","volume":"19","author":"TJ Schnitzer","year":"2011","unstructured":"Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT (2011) Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cartil 19(6):639\u2013646. https:\/\/doi.org\/10.1016\/j.joca.2011.01.009","journal-title":"Osteoarthr Cartil"},{"issue":"8","key":"5488_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jpain.2012.05.006","volume":"13","author":"MT Brown","year":"2012","unstructured":"Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR (2012) Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain 13(8):790\u2013798. https:\/\/doi.org\/10.1016\/j.jpain.2012.05.006","journal-title":"J Pain"},{"issue":"7","key":"5488_CR19","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.37950","volume":"65","author":"MT Brown","year":"2013","unstructured":"Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR (2013) Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum 65(7):1795\u20131803. https:\/\/doi.org\/10.1002\/art.37950","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5488_CR20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","volume":"154","author":"ELH Spierings","year":"2013","unstructured":"Spierings ELH, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR (2013) A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain 154(9):1603\u20131612. https:\/\/doi.org\/10.1016\/j.pain.2013.04.035","journal-title":"Pain"},{"issue":"1-2","key":"5488_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jns.2014.07.028","volume":"345","author":"MT Brown","year":"2014","unstructured":"Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, Verburg KM, Dyck PJ (2014) Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci 345(1-2):139\u2013147. https:\/\/doi.org\/10.1016\/j.jns.2014.07.028","journal-title":"J Neurol Sci"},{"issue":"11","key":"5488_CR22","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.3899\/jrheum.131294","volume":"41","author":"EF Ekman","year":"2014","unstructured":"Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, Brown MT, West CR, Verburg KM (2014) Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol 41(11):2249\u20132259. https:\/\/doi.org\/10.3899\/jrheum.131294","journal-title":"J Rheumatol"},{"issue":"6","key":"5488_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","volume":"74","author":"TJ Schnitzer","year":"2015","unstructured":"Schnitzer TJ, Ekman EF, Spierings ELH, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM, Kvien TK (2015) Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis 74(6):1202\u20131211. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204905","journal-title":"Ann Rheum Dis"},{"key":"5488_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/JPR.S135257","volume":"11","author":"C Birbara","year":"2018","unstructured":"Birbara C, Dabezies EJ, Burr AM, Fountaine RJ, Smith MD, Brown MT, West CR, Arends RH, Verburg KM (2018) Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis. J Pain Res 11:151\u2013164. https:\/\/doi.org\/10.2147\/JPR.S135257","journal-title":"J Pain Res"},{"issue":"1","key":"5488_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2019.8044","volume":"322","author":"TJ Schnitzer","year":"2019","unstructured":"Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM (2019) Effect of Tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. Jama 322(1):37\u201348. https:\/\/doi.org\/10.1001\/jama.2019.8044","journal-title":"Jama"},{"issue":"6","key":"5488_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/annrheumdis-2019-216296","volume":"79","author":"F Berenbaum","year":"2020","unstructured":"Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown MT, West CR, Verburg KM (2020) Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis 79(6):800\u2013810. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216296","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5488_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/0063030-200822060-00002","volume":"22","author":"JJ Watson","year":"2008","unstructured":"Watson JJ, Allen SJ, Dawbarn D (2008) Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22(6):349\u2013359. https:\/\/doi.org\/10.2165\/0063030-200822060-00002","journal-title":"BioDrugs"},{"key":"5488_CR28","doi-asserted-by":"publisher","unstructured":"M Z, S H, D S, M E, D F, M B (2011) A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol 59 (2):334-342. doi:https:\/\/doi.org\/10.1016\/j.yrtph.2010.11.005","DOI":"10.1016\/j.yrtph.2010.11.005"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05488-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:38:02Z","timestamp":1697049482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05488-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5488"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05488-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,6]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}